

FORM PTO/SB/08A/B (10-01) Substitute for PTO-1449A/B	Attorney Docket Number	58270/A400
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	N/A
	Filing Date	August 24, 2006
	Applicant(s)	Harukazu Kitagawa, et al.
	Group Art Unit	N/A
	Examiner Name	N/A

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (If Known)	Publication Date MM-DD-YYYY	Name of Patentee
/JE/		2003/0050268 A1	03-13-2003	Krieg, et al.
/JE/		2003/0087848 A1	05-08-2003	Bratzler, et al.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ - Number ⁴ - Kind Code ⁵ (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶ (<input checked="" type="checkbox"/>)
/JE/		JP 2003-510290	03-18-2003	Coley Pharmaceutical Group, Inc.	
/JE/		WO 2004/000351 A1	12-31-2003	Bachmann, et al.	

OTHER DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/JE/		International Search Report, dated 06-14-2005, corresponding to PCT/JP2005/003693
/JE/		KURAMOTO, ET AL., "Oligonucleotide Sequences Required for Natural Killer Cell Activation," Jpn. J Cancer Res., vol. 83, pages 1128-1131, November 1992
/JE/		GRUG, ET AL., "Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells," Eur. J. Immunol., vol 31, pages 2154-2163, 2001

AAM PAS697469.1--08/24/06 10:43 AM

EXAMINER SIGNATURE	/Janet Epps Ford/	DATE CONSIDERED	08/01/2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. ³ Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.			

FORM PTO/SB/08A/B (10-01)
Substitute for PTO-1449A/B



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Attorney Docket Number	58270/A400
Application Number	10/590,761
Filing Date	August 24, 2006
Applicant(s)	Harukazu Kitagawa, et al.
Group Art Unit	1632
Examiner Name	To be determined

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (If Known)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶ (<input checked="" type="checkbox"/>)
/JE/		JP 2002-510644	04-09-2002	Krieg et al.	Corresponds to WO 99/51259 listed below
/JE/		JP 2002-517156	06-11-2002	Schwartz et al.	Corresponds to WO 98/55495 listed below
/JE/		WO 98/55495	12-10-1998	Schwartz et al.	
/JE/		WO 99/51259	10-14-1999	Krieg et al.	
/JE/		WO 03/024480 A2	03-27-2003	Bachmann et al.	
/JE/		WO 03/024481 A3	03-27-2003	Maurer et al.	

OTHER DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/JE/		Iho, S., et al., <i>Oligodeoxynucleotides Containing Palindrome Sequences with Internal 5'-CpG-3' Act Directly on Human NK and Activated T Cells to Induce IFN-γ Production in Virto</i> , The The Journal of Immunology, (1999), pp 3642-3652

DLG PAS735869.1.-05/5/07 10:24 AM

EXAMINER SIGNATURE	/Janet Epps Ford/	DATE CONSIDERED	08/01/2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. ³ Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DBP/dg

FORM PTO/SB/08A/B (10-01)
Substitute for PTO-1449A/B

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Attorney Docket Number	58270/A400
Application Number	10/590,761
Filing Date	August 24, 2006
Applicant(s)	Harukazu Kitagawa, et al.
Group Art Unit	1633
Examiner Name	Janet L. Epps Ford

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (If Known)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶ (<input checked="" type="checkbox"/>)

OTHER DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/JE/		Tokunaga, T. et al., <i>Antihumor Activity of Deoxyribonucleic Acid Fraction From Mycobacterium bovis BCG. I. Isolation, Physicochemical Characterization, and Antitumor Activity</i> , J. Natl. Cancer Inst., Vol. 72, No. 4, April 1984, pp 955-962
/JE/		Yamamoto, S. et al., <i>Unique Palindromic Sequences in Synthetic Oligonucleotides Are Required to Induce INF and Augment INF-Mediated Natural Killer Activity</i> , The Journal of Immunology, Vol. 148, No. 12, June 15, 1992, pp 4072-4076
/JE/		Krieg AM. et al., <i>CpG motifs in bacterial DNA trigger direct B-cell activation</i> , Letters To Nature, Vol.374, April 6, 1995, pp 546-549
/JE/		Verthelyi, D. et al., <i>Differential signaling by CpG DNA in Cs and B cells: not just TLR9</i> , Trends In Immunology, Vol. 24, No. 10, October 2003, pp 519-522
/JE/		Ballas ZK. et al., <i>Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA</i> , The Journal of . Immunology., Vol. 157, 1996, pp 1840-1845
/JE/		Boggs RL. et al., <i>Characterization and Modulation of Immune Stimulation by Modified Oligonucleotides</i> , Antisense & Nucleic Acid Drug Development, Vol 7, 1997, pp 461-471
/JE/		Klinman DM. et al., <i>CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma</i> , Proc. Natl. Acad. Sci. U.S.A., Vol. 93, April 1996, pp 2879-2883

EXAMINER SIGNATURE	/Janet Epps Ford/	DATE CONSIDERED	08/01/2007
--------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. ³Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Attorney Docket Number	58270/A400
Application Number	10/590,761
Filing Date	August 24, 2006
Applicant(s)	Harukazu Kitagawa, et al.
Group Art Unit	1633
Examiner Name	Janet L. Epps Ford

OTHER DOCUMENTS

EXAMINER INITIALS	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/JE/		Halpern, M.D., et al., <i>Bacterial DNA Induces Murine Interferon-γ Production by Stimulation of Interleukin-12 and Tumor Necrosis Factor-α</i> , Cellular Immunology, Vol. 167, Article No. 0009, 1996, pp 72-78
/JE/		Bohle, B. et al., <i>Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro</i> , Eur. J. Immunol., Vol. 29, 1999, pp 2344-2353
/JE/		Iho, S. et al., <i>Oligodeoxynucleotides Containing Palindrome Sequences with Internal 5'-CpG-3' Act Directly on Human NK and Activated T Cells to Induce IFN-γ Production In Vitro</i> , The Journal of Immunology, Vol 163, 1999, pp 3642-3652
/JE/		Hartmann, G. et al., <i>Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo</i> , The Journal of Immunology, Vol. 164, 2000, pp 1617-1624
/JE/		Hemmi, H. et al., <i>A Toll-like receptor recognizes bacterial DNA</i> , letters to nature, Vol. 408, December 2000, pp 740-745
/JE/		Hornung, V. et al., <i>Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides</i> , The Journal of Immunology, Vol. 168, 2002, pp 4531-4537
/JE/		Hartmann, G. et al., <i>Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells</i> , The Journal of Immunology, Vol. 164, 2000, pp 944-952
/JE/		Takauji, R. et al., <i>CpG-DNA-induces IFN-α production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors</i> , Journal of Leukocyte Biology., Vol. 72, November 2002, pp 1011-1019
/JE/		Halpern, M.D., et al., <i>In vitro inhibition of murine IFNγ production by phosphorothioate deoxyguanosine oligomers</i> , Immunopharmacology, Vol. 29, 1995, pp 47-52
/JE/		Chace, J., et al., <i>Bacterial DNA-Induced NK Cell IFN-γ Production in Dependent on Macrophage Secretion of IL-12</i> , Clinical Immunology and Immunopathology, Vol. 84, No. 2, August 1997, pp 185-193, Article No. II974380

DLG PAS697875.1-*06/30/07 1:16 PM

EXAMINER SIGNATURE	/Janet Epps Ford/	DATE CONSIDERED	08/01/2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. ³ Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DBP/rjf